Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380769114> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4380769114 abstract "Introduction: Incliciran, a small interfering ribonucleic acid (siRNA), is the new modulator of the proprotein convertase subtilisin kexin 9 (PCSK9) that has proven safe and effective in reducing LDL-C and ASCVD. However, it is unclear if incliciran is superior to the already established PCSK9 monoclonal antibodies (mAb) in reducing major adverse cardiac events (MACE). Methods: We performed a meta-analysis of randomized controlled trials of patients with high cardiovascular risk who underwent PCSK9 inhibition by either mAb or siRNA. The primary outcome was the reduction of MACE. Results: Thirty RCTs with a total of 92,775 patients were included. For patients with a high cardiovascular risk profile, the modulation of PCSK9 by mAb decreases the risk of MACE (HR 0.84, 95% CI 0.8 - 0.89, p<0.0001) compared with statins and/or ezetimibe. Similar effects occurred when siRNA (HR 0.78, 95% CI 0.63 - 0.97, p=0.024) was compared to statins alone. The impact on MACE was no different between mAb and siRNA modulation of PCSK9 (p=0.49) (figure 1). When PCSK9 inhibitors were compared to statins monotherapy, only evolocumab and incliciran were statistically significant in reducing MACE (p<0.0001 and p=0.024, respectively). An additional analysis of all studies, including those with statins plus ezetimibe, showed that all therapies except bococicimab (p=0.309) reduced MACE (figure 2). Conclusions: This study suggests that PCSK9 inhibition by siRNA is as effective as mAb PCSK9 for reducing MACE in patients with a high cardiovascular risk profile, with the convenience of being administered twice a year." @default.
- W4380769114 created "2023-06-16" @default.
- W4380769114 creator A5031924103 @default.
- W4380769114 creator A5036271530 @default.
- W4380769114 creator A5045047636 @default.
- W4380769114 creator A5049256268 @default.
- W4380769114 creator A5055418902 @default.
- W4380769114 creator A5075532163 @default.
- W4380769114 creator A5075894945 @default.
- W4380769114 date "2022-11-08" @default.
- W4380769114 modified "2023-09-24" @default.
- W4380769114 title "Abstract 9624: Major Adverse Cardiac Events of PCSK9 Modulation by Monoclonal Antibodies vs Small Interfering Ribonucleic Acid Inhibitors. A Meta-Analysis of 92,775 Patients" @default.
- W4380769114 doi "https://doi.org/10.1161/circ.146.suppl_1.9624" @default.
- W4380769114 hasPublicationYear "2022" @default.
- W4380769114 type Work @default.
- W4380769114 citedByCount "0" @default.
- W4380769114 crossrefType "journal-article" @default.
- W4380769114 hasAuthorship W4380769114A5031924103 @default.
- W4380769114 hasAuthorship W4380769114A5036271530 @default.
- W4380769114 hasAuthorship W4380769114A5045047636 @default.
- W4380769114 hasAuthorship W4380769114A5049256268 @default.
- W4380769114 hasAuthorship W4380769114A5055418902 @default.
- W4380769114 hasAuthorship W4380769114A5075532163 @default.
- W4380769114 hasAuthorship W4380769114A5075894945 @default.
- W4380769114 hasConcept C104317684 @default.
- W4380769114 hasConcept C126322002 @default.
- W4380769114 hasConcept C22615655 @default.
- W4380769114 hasConcept C2776329913 @default.
- W4380769114 hasConcept C2776839432 @default.
- W4380769114 hasConcept C2778163477 @default.
- W4380769114 hasConcept C2778657065 @default.
- W4380769114 hasConcept C2778849439 @default.
- W4380769114 hasConcept C2780072125 @default.
- W4380769114 hasConcept C2780739214 @default.
- W4380769114 hasConcept C2780948078 @default.
- W4380769114 hasConcept C43554185 @default.
- W4380769114 hasConcept C45393284 @default.
- W4380769114 hasConcept C500558357 @default.
- W4380769114 hasConcept C55493867 @default.
- W4380769114 hasConcept C67705224 @default.
- W4380769114 hasConcept C71924100 @default.
- W4380769114 hasConcept C86803240 @default.
- W4380769114 hasConcept C98274493 @default.
- W4380769114 hasConceptScore W4380769114C104317684 @default.
- W4380769114 hasConceptScore W4380769114C126322002 @default.
- W4380769114 hasConceptScore W4380769114C22615655 @default.
- W4380769114 hasConceptScore W4380769114C2776329913 @default.
- W4380769114 hasConceptScore W4380769114C2776839432 @default.
- W4380769114 hasConceptScore W4380769114C2778163477 @default.
- W4380769114 hasConceptScore W4380769114C2778657065 @default.
- W4380769114 hasConceptScore W4380769114C2778849439 @default.
- W4380769114 hasConceptScore W4380769114C2780072125 @default.
- W4380769114 hasConceptScore W4380769114C2780739214 @default.
- W4380769114 hasConceptScore W4380769114C2780948078 @default.
- W4380769114 hasConceptScore W4380769114C43554185 @default.
- W4380769114 hasConceptScore W4380769114C45393284 @default.
- W4380769114 hasConceptScore W4380769114C500558357 @default.
- W4380769114 hasConceptScore W4380769114C55493867 @default.
- W4380769114 hasConceptScore W4380769114C67705224 @default.
- W4380769114 hasConceptScore W4380769114C71924100 @default.
- W4380769114 hasConceptScore W4380769114C86803240 @default.
- W4380769114 hasConceptScore W4380769114C98274493 @default.
- W4380769114 hasIssue "Suppl_1" @default.
- W4380769114 hasLocation W43807691141 @default.
- W4380769114 hasOpenAccess W4380769114 @default.
- W4380769114 hasPrimaryLocation W43807691141 @default.
- W4380769114 hasRelatedWork W2047327216 @default.
- W4380769114 hasRelatedWork W2053653961 @default.
- W4380769114 hasRelatedWork W2204366635 @default.
- W4380769114 hasRelatedWork W2524053332 @default.
- W4380769114 hasRelatedWork W2551669605 @default.
- W4380769114 hasRelatedWork W2724912765 @default.
- W4380769114 hasRelatedWork W2912784612 @default.
- W4380769114 hasRelatedWork W2914450987 @default.
- W4380769114 hasRelatedWork W2938776051 @default.
- W4380769114 hasRelatedWork W4281261930 @default.
- W4380769114 hasVolume "146" @default.
- W4380769114 isParatext "false" @default.
- W4380769114 isRetracted "false" @default.
- W4380769114 workType "article" @default.